Author: Petros Charalampoudis and Andreas Karakatsanis
The pivotal meta-analysis1 by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) provides high-quality data on the concept of risk-adapted breast-conserving therapy. The investigators showed equivalent survival in patients treated with the same chemotherapy before or after surgery, with a significantly higher frequency of local recurrence in patients receiving neoadjuvant chemotherapy (NACT) compared with the adjuvant group. This difference in local recurrence was not accompanied by a decrease in survival.
(See also the associated correspondence on the right hand menu)
